Th1 vs Th2 Responses: Mechanisms, Cytokines, and Disease Roles

Th1 and Th2 responses represent two fundamentally different modes of immune defense carried out by CD4+ helper T cells. Th1 cells specialize in activating macrophages and other defenses against bacteria, viruses, and other pathogens that invade your cells, while Th2 cells coordinate the immune response against parasites and are heavily involved in allergic reactions. The balance between these two arms shapes everything from whether you clear an infection to whether you develop autoimmune disease or allergies, and the biology behind that balance turns out to be more layered than the original framework suggested.

How a Naive T Cell Picks a Side

When a naive CD4+ T cell first encounters an antigen, it has not yet committed to being Th1 or Th2. The decision depends largely on signals from innate immune cells, especially dendritic cells, which act as scouts that detect threats and relay information to T cells. Dendritic cells play a central organizing role in determining which direction a T cell differentiates.

For Th1 commitment, the key signal is interleukin-12 (IL-12), a cytokine released by dendritic cells and macrophages when they detect intracellular pathogens. IL-12 activates a signaling protein called STAT4 inside the T cell, which then switches on the master transcription factor T-bet. T-bet essentially rewires the cell’s gene expression to produce Th1-associated cytokines.¹ Recent work has pinpointed the exact DNA element where STAT4 binds to turn on T-bet, confirming that this binding step is essential for Th1 differentiation to proceed.²

For Th2 commitment, the critical cytokine is IL-4, which activates a different transcription factor called GATA-3. The timing of this IL-4 signal matters: it needs to arrive early during T cell activation for the cell to commit to the Th2 lineage, because IL-4 triggers structural changes in the cell’s DNA packaging that open up the genes encoding Th2 cytokines.³ Miss that early window and the cell is far less likely to become a Th2 cell.

The Cytokines Each Type Produces

Once committed, Th1 and Th2 cells release very different sets of cytokines, and those cytokines activate different branches of the immune system.

Th1 cells primarily produce interferon-gamma (IFN-γ), which is their signature weapon. IFN-γ supercharges macrophages, the immune cells that engulf and destroy pathogens hiding inside your own cells. In the case of tuberculosis, for instance, IFN-γ promotes the maturation of the compartments macrophages use to digest bacteria, boosts the production of reactive oxygen and nitrogen species that kill microbes, and enhances the macrophage’s ability to present pieces of the pathogen to other immune cells.⁴ Th1 cells are also associated with delayed-type hypersensitivity reactions, the kind of slow-building inflammatory response you see with a tuberculin skin test.

Th2 cells produce a different cocktail: IL-4, IL-5, IL-6, and IL-13 are the major players.⁵ These cytokines steer the immune system toward antibody production (particularly the IgE class, which is central to allergic reactions) and toward activating eosinophils, a type of white blood cell that helps fight parasites but also drives much of the tissue damage in allergic disease. IL-13 in particular has a role beyond allergy: it stimulates tissue fibrosis by activating the production and processing of TGF-β1, a growth factor that drives scar-like tissue remodeling.⁶

How Th1 and Th2 Suppress Each Other

One of the defining features of the Th1/Th2 system is that it is mutually inhibitory. The transcription factors T-bet and GATA-3 do not just activate their own programs; they actively suppress the opposing one. Mathematical modeling of this system shows that antigen stimulation combined with cytokine signals creates a rapid, reversible, and mutually exclusive expression pattern: a cell expressing T-bet will suppress GATA-3, and vice versa, through feedback loops between the transcription factors and their signaling pathways.⁷ This creates what amounts to a binary switch at the single-cell level.⁸

At the whole-body level, the practical consequence is that a strong Th1 response tends to dampen Th2 activity, and a strong Th2 response tends to dampen Th1 activity. This tug-of-war has real clinical implications, especially when two infections that require opposite immune strategies occur in the same person.

Infections That Defined the Paradigm

The Th1/Th2 framework was largely built on studies of the parasite Leishmania major in mice during the 1980s. Researchers found that mouse strains mounting strong Th1 responses cleared the infection, while strains that skewed toward Th2 developed progressive, non-healing disease.⁹ This became the textbook example: Th1 for intracellular pathogens, Th2 for extracellular parasites.

The story got more complicated when researchers knocked out the IL-4 gene in mice and found that the absence of this signature Th2 cytokine did not always restore healing in susceptible strains, questioning whether Th2 dominance alone explained susceptibility.⁹ The Leishmania model remains a useful teaching tool, but the field has come to recognize that real infections involve more moving parts than a simple Th1/Th2 seesaw.

Tuberculosis provides another clear example. Effective defense against Mycobacterium tuberculosis requires a robust Th1 response, with IFN-γ activating macrophages to kill the bacteria hiding inside them.⁴ Anything that weakens that Th1 response, whether a genetic predisposition, a co-infection, or an immunosuppressive drug, can tip the balance toward disease progression.

What Happens When Worms Meet Tuberculosis

In much of the developing world, helminth (parasitic worm) infections overlap geographically with tuberculosis. This creates a natural experiment in Th1/Th2 cross-regulation. Helminths provoke strong Th2 responses, and as the mutual suppression would predict, people co-infected with helminths and TB often show weakened Th1 immunity against the tuberculosis bacteria. The immune responses induced by extracellular helminths and intracellular TB are often mutually antagonistic, which can impair the host’s ability to fight either infection effectively.¹⁰

Studies in co-infected individuals have measured this directly. People with helminth infections tend to produce less IFN-γ and TNF-α, the key Th1 cytokines needed to fight TB. The effect varies by helminth species: hookworm co-infection, for instance, was associated with significantly lower IFN-γ production compared to TB patients without worms.¹¹ This finding has prompted ongoing discussion about whether deworming programs in TB-endemic regions could improve tuberculosis outcomes by lifting the Th2-mediated brake on Th1 immunity.

Autoimmune Disease and Th1 Dominance

When Th1 responses are too aggressive or misdirected against the body’s own tissues, the result is autoimmune disease. Multiple sclerosis, type 1 diabetes, and rheumatoid arthritis have all been characterized as Th1-mediated conditions, driven by excessive IFN-γ production and the inflammatory cascades it triggers.¹² In these diseases, the immune system attacks myelin sheaths, insulin-producing beta cells, or joint tissues, respectively, through mechanisms that rely heavily on Th1-type inflammation.

The autoimmune connection is worth noting because it illustrates a broader principle: more Th1 is not always better. A person with a very strong Th1 bias might be excellent at clearing intracellular infections but more vulnerable to autoimmune attack. The immune system is not simply trying to be “strong”; it is trying to be balanced.

Allergic Disease and Th2 Dominance

On the other side of the balance, excessive or misplaced Th2 responses are the immunological engine behind allergic diseases. Asthma, allergic rhinitis, and atopic dermatitis are all driven by Th2 cytokines. In atopic dermatitis specifically, IL-4, IL-13, and IL-5 produced by Th2 cells create the characteristic features of the disease: itchy, inflamed skin, elevated IgE levels, and eosinophil infiltration.¹³ Research into the genetic and mechanistic underpinnings of atopic dermatitis has consistently found Th2 responses at the center of disease development.¹⁴

The IgE connection deserves attention because it explains why allergic people react so dramatically to harmless substances like pollen or dust mites. Th2 cytokines, especially IL-4, drive B cells to produce IgE antibodies. Those IgE molecules sit on the surface of mast cells, and the next time the allergen arrives, it cross-links the IgE and triggers the mast cell to dump histamine and other inflammatory mediators. The entire chain, from Th2 cell to IgE to mast cell to sneezing, traces back to a Th2-skewed immune posture.⁵

Beyond allergies, Th2-driven IL-13 can cause lasting structural damage to tissues through fibrosis. In animal models, IL-13 stimulates the production and activation of TGF-β1, a potent driver of scar-tissue formation. When this fibrotic pathway is blocked experimentally, the tissue damage diminishes substantially.⁶ This is relevant to chronic asthma, where repeated Th2-mediated inflammation leads to airway remodeling and permanently reduced lung function.

Th1/Th2 Balance in Cancer

Inside a tumor, the Th1/Th2 balance takes on a different significance. Th1 cells, through IFN-γ, are generally anti-tumor: they activate macrophages and cytotoxic T cells that can kill cancer cells. Th2 responses, by contrast, tend to be immunosuppressive in the tumor microenvironment. Research indicates that Th2 cells interfere with Th1’s anti-tumor function and promote the accumulation of myeloid-derived suppressor cells (MDSCs), a population of immune cells that suppress anti-cancer immunity. MDSCs, together with a type of macrophage driven by Th2 signals, help suppress Th1 and cytotoxic T cell activity within the tumor.¹⁵

This has practical implications for cancer immunotherapy. Many checkpoint inhibitors and adoptive cell therapies work, in part, by restoring or amplifying Th1-type responses inside the tumor. When a tumor successfully shifts the local immune environment toward Th2 dominance, it creates a kind of immune-privileged niche where it can grow with less interference.

The Framework Has Expanded

The original Th1/Th2 model, proposed in the late 1980s, was a breakthrough. But the immune system turned out to be less binary than those early experiments suggested. The discovery of Th17 cells, a distinct subset that produces IL-17 and plays a major role in defense against extracellular bacteria and fungi, forced a significant revision. The emergence of Th17 cells as a distinct lineage extended the concept of alternative developmental pathways for naive T cells and highlighted a degree of developmental plasticity that the original framework did not account for.¹⁶

Regulatory T cells (Tregs), which suppress immune responses rather than drive them, added another layer. Importantly, both Th17 and Treg cells show a high degree of plasticity: under certain conditions, a Th17 cell can shift toward a Treg phenotype or vice versa, and their differentiation is not necessarily a permanent endpoint.¹⁷ This plasticity means the immune system can adapt its response as conditions change during an infection or inflammatory episode.

The psoriasiform skin lesions that sometimes develop as a side effect of anti-TNF therapy in inflammatory bowel disease patients illustrate how Th1 and Th17 responses can intertwine in unexpected ways. These lesions are characterized by both IFN-γ-expressing Th1 cells and IL-17-producing Th17 cells, and they respond to antibodies that target the shared IL-12/IL-23 pathway.¹⁸ Real-world immune pathology rarely respects clean Th1/Th2 boundaries.

Different Metabolic Wiring

One of the more surprising differences between Th1 and Th2 cells is not about which cytokines they produce but about how they fuel themselves. Th1 cells rely heavily on aerobic glycolysis, the rapid breakdown of glucose even when oxygen is available, a metabolic strategy shared with many rapidly dividing cells. Th2 cells run at similar levels of oxidative metabolism but use significantly less glycolysis, making them less dependent on glucose and more reliant on fatty acid uptake for energy.¹⁹

This difference has real consequences. In helminth infection models, Th2 cells activated in living tissue do not ramp up glycolysis the way Th1 cells would; instead, they increase their oxidative metabolism and fatty acid uptake.²⁰ Because of this, Th1 cells are more vulnerable to drugs or conditions that block glycolysis, while Th2 cells can tolerate higher concentrations of glycolysis inhibitors before dying.¹⁹ These metabolic differences are conserved across species, suggesting they are a fundamental feature of how each lineage operates rather than a quirk of one model organism.

This matters for drug development. If you could selectively starve Th2 cells of fatty acids without affecting Th1 cells, you might dampen allergic responses while leaving anti-pathogen immunity intact. Conversely, metabolic interventions that interfere with glycolysis could disproportionately affect Th1-mediated autoimmune conditions. The field of immunometabolism is still young, but these lineage-specific metabolic preferences are a promising avenue for more precise immune therapies.

Why Th2 Evolved in the First Place

The traditional explanation for Th2 immunity is straightforward: it evolved to fight parasitic worms. But more recent thinking suggests a reframing. The fundamental evolutionary driver of Th2 immunity may not have been killing parasites directly but rather repairing the tissue damage they cause. Migrating worms tear through barrier tissues like the gut lining and lungs. The Th2 response, with its wound-healing cytokines and mucus production, may have evolved primarily as a rapid tissue-repair program that also happens to help expel worms.²¹ Under this view, allergic reactions are misfires of a system that evolved to patch up barrier tissues, not an immune defense looking for parasites that are no longer there (though the “hygiene hypothesis” reading is not entirely wrong either).

Targeting Th2 Cytokines With Drugs

The clinical payoff of understanding Th1/Th2 biology is already visible in the allergy and respiratory disease clinic. Drugs that block specific Th2 cytokines have become some of the most successful biologic therapies in recent years. In COPD, for example, clinical trials have tested several approaches: drugs targeting IL-5 alone (mepolizumab) or its receptor (benralizumab) produced modest reductions in exacerbations in patients with eosinophil-high disease, while dupilumab, which blocks the IL-4 receptor and thereby inhibits both IL-4 and IL-13 signaling, reduced exacerbations by about 30% in patients with elevated eosinophil counts.²² The broader blockade of dupilumab outperformed the narrower anti-IL-5 approach, underscoring that Th2-driven inflammation involves multiple cytokines acting in concert rather than a single culprit.

On the Th1 side, ustekinumab, an antibody targeting the shared p40 subunit of IL-12 and IL-23, has proven effective for conditions involving both Th1 and Th17 pathways. In patients with Crohn’s disease who developed severe psoriasiform skin lesions as a side effect of anti-TNF therapy, ustekinumab achieved a 100% response rate in a small series of nine patients.¹⁸ By blocking IL-12, the cytokine that initiates Th1 differentiation, the drug cuts off the Th1 response at its source.

How Aging Shifts the Balance

The Th1/Th2 balance is not static over a lifetime. Aging appears to push the immune system toward Th2 dominance. In studies of human blood samples, the percentage of IFN-γ-producing (Th1-type) CD4+ T cells drops with age, both in naive T cells and in the activated memory pool. At the same time, IL-4-producing (Th2-type) cells increase, particularly among memory T cells in the oldest individuals studied.²³ A separate line of evidence comes from invariant natural killer T cells, a specialized immune cell type, which also show a Th1-to-Th2 shift in their cytokine profile with aging.²⁴

This age-related shift may help explain several patterns seen in older adults. The decline in Th1 function could contribute to increased susceptibility to intracellular infections like tuberculosis and certain viral illnesses. At the same time, the rise in Th2 activity does not necessarily translate to more allergies in old age, because the overall immune system is also losing potency (a process called immunosenescence). The shift is one piece of a larger puzzle that includes declining T cell diversity, chronic low-grade inflammation, and reduced vaccine responsiveness. Still, the Th1-to-Th2 drift is one of the more consistent immunological findings in aging research and has attracted interest as a potential target for interventions aimed at improving immune function in older people.

Epigenetic Locks on Cell Identity

Once a T cell commits to the Th1 or Th2 lineage, the decision is reinforced at the level of DNA packaging. The regions of DNA encoding Th1 or Th2 cytokines undergo chromatin remodeling: the DNA around active genes gets loosened so those genes can be read, while the DNA around the opposing lineage’s genes gets compacted and silenced. These epigenetic changes accumulate over multiple rounds of cell division and become increasingly difficult to reverse, effectively locking the cell into its chosen identity.²⁵ This is why, for example, a memory Th2 cell reactivated years after initial exposure will still produce IL-4 and IL-13 rather than switching to IFN-γ. The transcription factors T-bet and GATA-3 get the differentiation started, but the epigenetic modifications make the commitment durable across the cell’s lifetime and through subsequent generations of daughter cells.